Cocaine abuse
disease diseaseOn this page
Summary
Cocaine abuse (MONDO:0004456) is a disease and 46 clinical trials. Top therapeutic interventions include carbidopa anhydrous, cocaine, and levodopa. A subtype of substance abuse — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 46
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cocaine abuse |
| Mondo ID | MONDO:0004456 |
| DOID | DOID:809 |
| ICD-10-CM | F14.1 |
| SNOMED CT | 78267003 |
| UMLS | C0009171 |
| MedGen | 3136 |
| Is cancer (heuristic) | no |
Disease family
This is a subtype of substance abuse. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › substance-related disorder › substance abuse › cocaine abuse
Related subtypes (7): opioid abuse, antidepressant type abuse, hallucinogen abuse, alcohol abuse, amphetamine abuse, barbiturate abuse, phencyclidine abuse
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 46.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 21 |
| PHASE1 | 15 |
| PHASE2 | 7 |
| EARLY_PHASE1 | 2 |
| PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00223236 | PHASE3 | COMPLETED | Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/Dependence |
| NCT00218023 | PHASE2 | COMPLETED | Medications for Stopping Cocaine Dependence and Preventing Relapse |
| NCT00218036 | PHASE2 | TERMINATED | Pharmacotherapy Dosing Regimen in Cocaine and Opiate Dependent Individuals - 8 |
| NCT00218075 | PHASE2 | COMPLETED | Behavioral Therapy Combined With Carbidopa/Levodopa for the Treatment of Cocaine Dependence |
| NCT00227903 | PHASE2 | COMPLETED | Therapeutic Substance Abuse Treatment in Pregnancy - 1 |
| NCT00373880 | PHASE2 | COMPLETED | Effects of Aripiprazole on Cocaine Craving and Self-Administration |
| NCT01327586 | PHASE2 | COMPLETED | Abstinence-Linked Money Management Multisite |
| NCT06045793 | PHASE2 | TERMINATED | Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) |
| NCT00218049 | PHASE1 | TERMINATED | Interaction Between Vanoxerine (GBR 12909) and Cocaine in Cocaine Dependent Individuals |
| NCT00292123 | PHASE1 | COMPLETED | Combined Behavioral and Pharmacologic Treatment of Polydrug Abuse |
| NCT00318760 | PHASE1 | COMPLETED | Effect of Clonidine on Responses to Imagery Scripts |
| NCT00350610 | PHASE1 | COMPLETED | Computer-Based Training in Cognitive Behavior Therapy |
| NCT00350870 | PHASE1 | COMPLETED | CBT With Disulfiram and Contingency Management |
| NCT00842517 | PHASE1 | COMPLETED | Long Term Maintenance of Drug Abstinence |
| NCT01030692 | PHASE1 | COMPLETED | Rivastigmine and Huperzine A as Treatments for Cocaine Dependence |
| NCT01062945 | PHASE1 | COMPLETED | The Effects of Doxazosin on the Cardiovascular and Subjective Effects of Cocaine |
| NCT01366001 | PHASE1 | COMPLETED | ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine |
| NCT01437293 | PHASE1 | COMPLETED | Behavioral and Physiological Effects of Cocaine in Cocaine-dependent Participants Treated With Levodopa in Combination With Carbidopa and Entacapone (LCE) |
| NCT01601730 | PHASE1 | COMPLETED | Modafinil - Escitalopram Study for Cocaine Dependence |
| NCT01651364 | PHASE1 | COMPLETED | A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence |
| NCT01651377 | PHASE1 | COMPLETED | Pramipexole as a Treatment for Cocaine Dependence |
| NCT02393599 | PHASE1 | COMPLETED | Study to Assess Potential Interactions Between Intravenous Cocaine and Oral Lorcaserin |
| NCT02563769 | PHASE1 | COMPLETED | Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study |
| NCT02141620 | EARLY_PHASE1 | COMPLETED | n-Acetylcysteine and Cocaine |
| NCT02233829 | EARLY_PHASE1 | WITHDRAWN | Dopamine Rhythms in Health and Addiction |
| NCT00439049 | Not specified | RECRUITING | Substance Abuse Pre-Treatment Screening Study |
| NCT00142883 | Not specified | TERMINATED | The Effects of GABA Enhancing Medications on Individuals Addicted to Cocaine - 3 |
| NCT00217997 | Not specified | COMPLETED | Impulsivity, Brain Function, and Substance Abuse Treatment in Cocaine Dependent Individuals |
| NCT00218257 | Not specified | COMPLETED | Progesterone for the Treatment of Cocaine Dependence - 1 |
| NCT00249457 | Not specified | COMPLETED | Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 2 |
| NCT00429767 | Not specified | COMPLETED | Sustained Release d-Amphetamine & Buprenorphine on Drug Seeking Behavior in Opioid & Cocaine Dependent Individuals |
| NCT00606801 | Not specified | COMPLETED | Galantamine Effects on Cognitive Function in Abstinent Cocaine Users |
| NCT00631748 | Not specified | COMPLETED | Quetiapine for the Reduction of Cocaine Use |
| NCT00698737 | Not specified | COMPLETED | Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC) |
| NCT00865332 | Not specified | WITHDRAWN | Psychology of Reward and Punishment: Functional and Molecular Brain Imaging and Monoaminergic Correlates |
| NCT00946660 | Not specified | COMPLETED | Non-Treatment Study of Factors Affecting Cocaine Drug Choice |
| NCT01010620 | Not specified | COMPLETED | Screening Protocol for Research Participants |
| NCT01249274 | Not specified | COMPLETED | Progesterone for Postpartum Cocaine Relapse |
| NCT01392092 | Not specified | COMPLETED | Effects of N-acetylcysteine on Brain Chemistry and Behavior in Cocaine Abusers (NAC) |
| NCT01401270 | Not specified | COMPLETED | Prize Contingency Management for Cocaine-Dependent Methadone Patients |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBIDOPA ANHYDROUS | 4 | 9 |
| COCAINE | 4 | 4 |
| LEVODOPA | 4 | 4 |
| CITALOPRAM | 4 | 3 |
| DOXAZOSIN | 4 | 3 |
| RIVASTIGMINE | 4 | 3 |
| MODAFINIL | 4 | 2 |
| QUETIAPINE | 4 | 2 |
| CABERGOLINE | 4 | 1 |
| CLAVULANIC ACID | 4 | 1 |
| DEXTROAMPHETAMINE | 4 | 1 |
| DISULFIRAM | 4 | 1 |
| GALANTAMINE | 4 | 1 |
| LORCASERIN | 4 | 1 |
| PRAMIPEXOLE | 4 | 1 |
| SAMIDORPHAN | 4 | 1 |
| CITICOLINE | 3 | 2 |
| DEXPRAMIPEXOLE | 3 | 1 |
| VANOXERINE | 3 | 1 |
| HUPERZINE A | 2 | 1 |
| CHEMBL351042 | 0 | 2 |
| CHEMBL498563 | 0 | 1 |
| CHEMBL5417591 | 0 | 1 |
| CHEMBL394259 | 0 | 1 |
| CHEMBL4593105 | 0 | 1 |
| CHEMBL5192470 | 0 | 1 |
| CHEMBL1201343 | 0 | 1 |
| CHEMBL1385 | 0 | 1 |
| CHEMBL3764305 | 0 | 1 |